Matricelf Ltd
TASE:MTLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rossari Biotech Ltd
NSE:ROSSARI
|
IN |
Matricelf Ltd
Revenue
Matricelf Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Revenue
₪0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Revenue
$180.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Revenue
$109.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Revenue
$42k
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Revenue
$1.3m
|
CAGR 3-Years
61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
Matricelf Ltd
Glance View
Matricelf Ltd. engages in research and development of technology in the field of regenerative medicine. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
See Also
What is Matricelf Ltd's Revenue?
Revenue
0
ILS
Based on the financial report for Dec 31, 2024, Matricelf Ltd's Revenue amounts to 0 ILS.
